Related Experiment Videos
[Clinical development of OCT]
Yoshiharu Yamada1, Tadao Akizawa, Kiyoshi Kurokawa
1Clinical Affairs Dept. Chugai Phamaceutical Co., LTD.
Clinical Calcium
|March 19, 2005
Summary
Octacalcium phosphate (OCP) effectively treats secondary hyperparathyroidism in dialysis patients by lowering PTH levels and improving bone health. Its favorable safety profile, with only a minor increase in serum calcium, led to manufacturing approval.
Area of Science:
- Nephrology
- Endocrinology
- Bone Metabolism
Context:
- Secondary hyperparathyroidism is a common complication in patients undergoing long-term dialysis.
- Managing elevated parathyroid hormone (PTH) levels and associated bone disease is crucial for patient outcomes.
Purpose:
- To evaluate the efficacy and safety of Octacalcium phosphate (OCP) in treating secondary hyperparathyroidism in long-term dialysis patients.
- To assess the impact of OCP on PTH levels, bone tissue, and bone metabolic markers.
Summary:
- Clinical development of OCP began in 1991, involving 15 studies with 977 participants, including comparative and long-term administration trials.
- OCP demonstrated significant reduction in PTH levels and ameliorative effects on high bone turnover and bone metabolic markers.
- Safety evaluation revealed no major drawbacks, with only a noted increase in serum calcium levels.
Impact:
- OCP (Oxarol injection) received manufacturing approval in July 2000, offering a new therapeutic option for secondary hyperparathyroidism in dialysis patients.
- The drug's efficacy in managing bone complications associated with chronic kidney disease is supported by extensive clinical data.